8-K: Rapport Therapeutics Files for $110M Stock Offering

Rapport Therapeutics, Inc. filed a prospectus supplement to register the offer and sale of up to $110 million in common stock through sales agents.

Summary

• Rapport Therapeutics, Inc. filed a prospectus supplement on January 7, 2026, to its effective shelf registration statement on Form S-3.
• The purpose of the supplement is to register the offer and sale of common stock with an aggregate offering price of up to $110,000,000.
• The shares will be offered and sold from time to time through Leerink Partners LLC and Cantor Fitzgerald & Co. (Sales Agents).
• This offering is pursuant to an existing Sales Agreement dated July 1, 2025, between the Company and the Sales Agents.
• As of the date of this Current Report on Form 8-K, no sales of the Company's common stock have been made under the Sales Agreement.
• The original Registration Statement on Form S-3 (File No. 333-288444) was filed on July 1, 2025, and declared effective on July 9, 2025, covering up to $400,000,000 of various securities.
• Goodwin Procter LLP provided an opinion confirming that the shares have been duly authorized and, upon future approval and issuance, will be validly issued, fully paid, and nonassessable.

Sentiment

Score: 5

Explanation: The filing is procedural, announcing a mechanism for a potential future capital raise. It does not contain operational or financial results, thus maintaining a neutral sentiment.

Positives

• The filing demonstrates the company's ability to access capital markets, providing flexibility for future funding needs.
• The shelf registration mechanism allows the company to raise capital efficiently over time as opportunities arise.

Negatives

• The potential sale of up to $110,000,000 in common stock could lead to dilution for existing shareholders.

Future Outlook

The company intends to offer and sell shares of its common stock with an aggregate offering price of up to $110,000,000 from time to time, indicating a future capital raising activity.

Industry Context

This filing represents a standard procedural step for publicly traded companies to establish a mechanism for future capital raises. Utilizing a shelf registration statement and an 'at-the-market' (ATM) offering facility provides companies with flexibility to access capital as needed, which is a common practice across various industries, particularly for growth-oriented or development-stage companies.

Stakeholder Impact

• Shareholders: Potential for dilution if new shares are issued, which could impact earnings per share and ownership percentage.

Next Steps

• The company may proceed with the offer and sale of up to $110,000,000 in common stock through its sales agents at market prices.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Common Stock, Equity Offering, Shelf Registration, Prospectus Supplement, Capital Raise, SEC Filing, Form S-3, Form 8-K